Disclosed is the use of CD37-specific binding molecule and/or mTOR inhibitor in the manufacture of a composition for treating a B-cell lymphoma or leukemia a disease characterised by inappropriate T cell stimulation associated with a B-cell pathway in a patient in need thereof, wherein the composition is comprised of an effective amount of CD37-specific binding molecule and/or mTOR and wherein the composition is to be administered prior to, simultaneous with or subsequent to an amount of an mTOR/CD37-specific binding molecule. Further discloses a composition comprising mTOR and CD37-specific binding molecule.
